Bladder cancer remains one of the most prevalent types of cancers on the planet. Back in 2020, an estimated 212,536 people died from bladder cancer all over the world, according to a report from cancer.net. CG Oncology is a company that is aiming to reduce that lofty number by giving patients access to a drug that could be a game changer in this field.
The Business Research Company recently estimated that the global bladder cancer drugs market was worth $3.63 billion in 2023. That same report projected that this market would reach a value of $4.23 billion in 2024, which would represent year-over-year compound annual growth rate of 15.8%. Meanwhile, the report estimated that this market would reach $7.28 billion by 2028. That would represent a CAGR of 14.5% over that five-year period.
CG Oncology is an oncolytic immunotherapy company that is based in California. The company is focused on developing bladder saving therapeutics for patients suffering from the affliction. An oncolytic virus developed by CG Oncology eliminated tumours in 64% of 66 patients with bladder cancer that did not respond to mainline treatment. Last month, the United States Food and Drug Administration (FDA) granted fast track designation breakthrough designation to the company’s cretostimogene grenadenorepvec to treat patients with Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).
On January 2, 2024, CG Oncology announced that it had filed for an initial public offering (IPO) with the Securities and Exchange Commission (SEC).
